Xarelto

Active substance

Rivaroxaban

Holder

Bayer

Status

Closed

Indication

Co-administered with acetylsalicylic acid (ASA), for the treatment of patients with coronary artery disease (CAD) at high risk of ischaemic events

Public documents

Approbation

Information for the patient

Informed consent

Last update

21/08/2020